From Detection Technology, and welcome to follow its fourth quarter results announcement. I'm pleased to be presenting it to you.
Fourth quarter net sales reached €29.7 million, a 6% decrease. EBITDA was €3.7 million, and the EBITDA percentage was 12.44%. So, it was approximately 1.5 million below what we achieved last year.
The biggest reason for the sales decline was the currency exchange rate, which represents about 5.5%. So without that, the sales would be very much flattish.
But we'll be explaining a bit closer what took place. So, looking at the applications point of view, sales in Medical developed quite well. But then in security declined. Industrial sales were 7% negative, but there was very strong growth in flat panels. TFT was even 50% for the quarter and actually for the full year, 60% growth. This was driven especially by battery inspection in APAC.
And then line-scan sales were declining, while medical sales grew by 19%, showing very strong growth driven by CT. And also the healthcare reform in China is now in action. And that is then also driving the growth in China.
Security -29% looks a bit harsh. Big number. But actually, this is very much an outcome of certain one-time events. And also, we must remember that the fourth quarter in 2024 was fairly high, exceptionally high in security, as well as in 2023. So, there's some seasonality involved, and the biggest single item for the decline in security was the European 100ml effect.
The European 100ml Liquid Rule effect was still affecting the fourth quarter.
Now it's past. Also, we had fairly sizable inventories with a couple of customers. And that's now also past.
And then also relating to security. The market was very soft, especially in China.
Typically, the fourth quarter is the best.
However, this year, 2025, sales saw a 6% decline compared to the previous year, which also resulted in lower profitability. So with smaller sales and especially the sales very much focusing on Medical, where profitability is lower, this affected the overall outcome. We had 12.4% EBITDA.
From a market point of view. AMERICAS was flattish. APAC. APAC declined by 4.4%. Despite that, the medical was strong there.
But then on the other side, security and industrial were weaker.
And then Europe, down 12%, clearly driven by the security point; it is worth noting here that precisely two-thirds of our sales are in APAC. And the economies in APAC actually grow at double the rate compared to those in the Western world. This is a good position to have. Then, from an application point of view, Industrial was down, Medical was up 19%, and Security was down almost 30%.
And here, clearly, you can see that medical is representing 50% of sales. And that's exceptional if you look also in our history. For the full year, net sales were 101 million, down 6%. EBITDA was 9.6 million, representing 9.55%. Actually, the biggest impact there is the currency exchange rate that affects more than half of this decline. Full year AMERICAS -22% APAC flat, EMEIA -16%. And both EMEIA and AMERICAS, by the way, are driven by the weak security segment performance.
Looking then more closely at the finances. EBITDA 3.7 versus last year 5.2. EBITDA for the full year was €12.4 million compared to €6.6 million last year, and EBIT for Q4 was €1.3 million. We did not have any non-recurring items. So this is clear from that point of view. And also I want to highlight that we are recognizing all R&D as cost. So the full R&D spending, which clearly is an investment but it's not capitalized. So, as a cost, it was €2.8 million, and for the full year, it was €11.3 million, representing 11.2% of our sales. Cash flow was down quite sizably. And the reason there is that we are on purpose, we have been increasing our inventories to be ready for supporting the growth in the challenging global markets, where actually there are sudden shortages of materials. For example, investments were quite reasonable, reaching $900,000 for the quarter and $2.3 million for the full year, and then the return on investment. Still quite okay, 9.2%, and the earnings per share were €0.22 for the quarter.
We just launched our Deetee 2030 strategy in November in our Capital Markets Day.
As a reminder, our target is to outgrow the market. The market grows 3%.
We aim to have 10% market share and to provide higher value-added, data-generating X-ray detectors through outstanding interfaces, usability, and services for our customers. Markets are driven by aging populations, security concerns, quality and efficiency, eco and circular economies, shortage of raw materials, and overall, machine learning, AI, and digitalization are driving the use of detectors. You can learn much more what's going on through clever use of AI. Out of the markets, clearly the biggest by application is healthcare at 70%. And then, security and industrial, representing a bit over 10% of the market, by technology, DT is strongest in line scan and CT, which are fast and very precise scanning methods. We are market leaders there. And then the TFT panel market, which is a more static part of the digital X-ray market, represents 40%, making it the biggest at almost 1.5 billion out of the 3 billion estimated market for 2030.
So we now have a very good position. Our business for the future will be more balanced because we have good products for all of these various technologies and applications.
Strategy.
In a nutshell, we are building on top of high-performing people through excellent customer interface. And the four cornerstones are the improvements in basic operations; R&D becoming faster, more productive, and increasing overall productivity; marketing and selling; and building TFT panels not only in China. Where our growth has clearly been strongest so far, but then also globally adding value to our products, being active with customers, finding ways how we can also build up software capabilities with them, and all is typically built on top of our hardware.
And then we are looking for the new technology like Photon counting for the 2030 and beyond.
As an example, we are looking back last year at what we achieved. The big things: in the middle, you see the heart. That's India. So we actually had the inauguration of the India factory in December. And now we are ready to provide locally made products for Indian markets.
We were awarded a very important recognition. GE Healthcare is the number one in the healthcare industry, highly reputable. And we were selected out of more than 20,000 suppliers as GE's Supplier of the Year. By the way, spending about 10 billion into their sourcing. So this is a sizable recognition.
And then we developed a new Photon counting CT detector and associated data management solutions, also creating a new low-cost product, AVA, for line-scan applications, and focusing on sustainability. We were awarded Ecovadis bronze with a score of 63. And by the way, only about 2% of the companies applying and being awarded this reach bronze or better. So this is a very good position to start.
Sales expectations. Now, for the first quarter and first half, I think we are full of energy and looking positively, because we have a quite nice outlook for the first quarter.
We see that all our applications are growing: Industrial, Medical, and Security. All our regions. We are officially guiding double-digit growth, not only for the first quarter, but also for the first half of this year. Regarding the dividends, the board is proposing a €0.30 dividend, which represents 68% of the net proceedings. The financial targets remain the same: at least 10% growth and at least 15% of EBITA, and the dividend percentage is between 30% to 60% of net proceeds as guidance.
I have a couple of questions.
I'm very happy and pleased to answer any questions you might have.